Nippon Zoki Pharmaceutical Co., Ltd.;Hyogo College of Medicine
发明人:
MATSUYAMA, Tomohiro,NAKAGOMI, Takayuki,FUKUDA, Yu
申请号：
AU2018394182
公开号：
AU2018394182A1
申请日:
2018.12.27
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The purpose of the present invention is to provide a lipocalin-type prostaglandin D2 synthase (L-PGDS) production accelerating agent, more specifically, an L-PGDS production accelerating agent in pericytes or ischemia-induced multipotent stem cells (iSC) de-differentiated from pericytes. The present invention has verified that a substance having an L-PGDS production accelerating effect is contained in an extract of inflammatory tissues inoculated with vaccinia virus. The L-PGDS production accelerating agent according to the present invention is highly useful as a drug or the like for prevention, treatment, or relapse prevention of disorders on which the enhanced expression of L-PGDS is expected to be effective, more specifically, cerebral vascular disorders such as brain infarction, dementia such as Alzheimer's disease, or sleep disorder.
